



Vancouver, British Columbia / November 3, 2016 – Pacific North West Capital Corp. (“PFN” the “Company”) (TSXV: PFN; OTCQB: PAWEF; FSE: P7J) is pleased to announce staking of 14 New, Unpatented Mining Claims, adjacent to its River Valley PGM Project (RVP) and north of its Recently Expanded River Valley Extension Project (Figure 1). The River Valley Platinum Metal Group (PGM) Deposit, on RVP, has been targeted by many drill campaigns, since 2000, which have returned High Grade Assays, at Shallow Depths and led to several large mineral resource estimates and positive metallurgical studies (for details see PFN websitewww.PFNCapital.com). Collectively, the Newly Expanded RVP, plus the Recently Acquired and Expanded River Valley Extension Project (see:Press Release October 5th, 2016) now comprise a total landholding of 10,454 ha. This large landholding gives PFN a Strategic Land Position and district scale PGM potential, near Sudbury, home to one of the World’s Largest Nickel-Copper-PGM Mining and Metallurgical Complexes.
The Expanded RVP overlies more of the interior of the River Valley Intrusion, in addition to the basal contact area. PGM Exploration has focused on the basal contact, hosted main mineralized trend and a very large, near-surface mineral resource has been delineated. However, the internal portion of the River Valley Intrusion, has not been systematically explored, despite the presence of high-grade PGM grab samples, mineralization in sporadic drilling, and geophysical anomalies. Approximately $10M in assessment credits can be applied to the claims, within the RVP property, allowing PFN to Focus Exploration on the Highest Priority Targets. Exploration is Underway and a Drill Program began in early October; results will be released in the Coming Weeks and Months.
Figure 1: Geological map showing the location of PFN’s newly expanded River Valley and River Valley Extension Projects, within 100 road-kms of Sudbury (Ontario). Note that the River Valley PGM deposit extends for a strike length of 16 km, is up to 200 metres wide and is open at depth.
About PFN’s Platinum Group Metals Division
River Valley is Canada’s Largest Undeveloped Primary PGM Deposit.
Achievements to date and Future Plans, for River Valley, are outlined below as follows:
Include more than 600 holes drilled, since year 2000, and several Mineral Resource Estimates and Metallurgical Studies
– Prepared by Tetra Tech (Wardrop)
– High Confidence: Measured plus Indicated = 72% of total
– Reported on PdEq basis: Pd=40% & Pt=20% of the Payable Metals
– Pd to Pt ratio = 2.5:1; Cu to Ni ratio = 3:1
– High Grade Potential: particularly in the north part of the River Valley Deposit
Resources under Evaluation for Development Potential as Open Pit Mining Operation
-Drill hole intercepts much higher than the average grade, of current Mineral Resource Estimate
-Possible New Mineralized Zone at the north end of the River Valley Deposit
-Show potential to take the River Valley PGM Project in a New Direction
-More drilling required and field crews have completed ground-proofing targets, to better plan Fall and Winter Drill Programs
-Mineral Prospecting and Geological Mapping on surface: In Progress
-Drill Programs targeted to add more, higher grade: Drilling Started October 2016
-Geological Interpretation and 2D/3D Modelling of all Drill and Surface Results
-Ongoing Strategic Partner Search for River Valley
About PFN’s Lithium Division
The Company’s Lithium Division will focus on the Discovery, Acquisition, Exploration and Development of Lithium Projects in Canada. In the United States, the Company will use its wholly owned U.S.A subsidiary to Acquire and Develop Projects, in Active Mining Camps, in Nevada, Arizona and California.
Management believes that these New Age Metals, Lithium, PGMs and Rare Earths, have robust macro trends with surging demands and limited supply. Going forward, this New Division will Explore for the Minerals needed to fuel the demand for Energy Storage and other Core 21st Century Technologies.
The Company has a Growing Portfolio of Lithium Projects: The Clayton Valley Forks Li Project, in Nevada, is a recent Lithium Brine Project, Acquired by the Company (see PFN News Releases: April 25th, 2016 and May 9th, 2016). The Company also has several Hard Rock Lithium Projects in Canada: To date the Company has Acquired 5 Hard Rock Lithium Projects, in the Winnipeg River Pegmatite Field, in SE Manitoba(see PFN News Releases: April 21st, 2016;May24th, 2016; June 15th, 2016; July 5th, 2016 and July 21st, 2016). This Pegmatite Field hosts the Giant Tanco Pegmatite Mine that has been mined for Tantalum, Cesium and Spodumene (one of the Primary Lithium Ore Minerals) in varying capacities, since 1969. Today, the Tanco Mine is focused on the Mining and Production of Cesium Formate, a drilling fluid for the petroleum industry. PFN’s Li Projects are strategically situated to Further Explore this Pegmatite Field.Presently, the Company is the Largest Claim Holder in the Winnipeg River Pegmatite Field.
Lithium and Platinum Group Metal Prices have improved drastically, in recent months. Lithium supplies remain in deficit, relative to their demand. Both Metals Groups are used for the expanding worldwide automobile industry (conventional and electric). In the case of PGM’s, demand is increasing for Autocatalysts, a key component for reducing toxic emissions, for automotive, gasoline and diesel engines. Regarding Lithium, there is an ever increasing demand for batteries in cellphones, laptops, electric cars, solar storage, wireless charging and renewable energy products.
Figure 3: PFN’s 5 New Lithium Projects in Manitoba, Surrounding Tanco Mine
Figure 4: Company Claim Blocks in the Clayton Valley area of Nevada
(Figure 4 is a Company-made composite and not intended for redistribution.
The Company accepts no responsibility for the accuracy of these claim blocks, other than the claim block associated with the Clayton Valley Forks Li Project)
Clayton Valley is located in Esmeralda County, Nevada, host to the Albemarle Corporation’s Silver Peak Lithium Mine and Brine Processing Operations. The mine has been in operation since 1967 and remains the only Brine-Based Lithium Producer in North America. The New Project Acquisition, in Nevada, provides the Company a Project, in an area that is well known for its Lithium Carbonate Production. Clayton Valley is a Centralized Location in Nevada, with Highway Access, Power Infrastructure, Water and Local Labor.
The company’s new Lithium Brine Project will be approximately 3.5 hours away from Tesla’s Gigafactory, which has a planned annual Lithium-ion battery production capacity of 35 gigawatt-hours per year, by 2020. The CV West Li Project is located approximately 3 hours north of the Faraday Electric Car Factory, to be operated in Las Vegas, Nevada.
Clayton Valley is one of the few locations globally, known to contain Commercial-Grade Lithium-Enriched Brines.
QUALIFIED PERSON
The contents contained herein, which relate to Exploration Results or Mineral Resources, is based on information compiled, reviewed or prepared by Dr. Bill Stone, Principal Consulting Geoscientist, for Pacific North West Capital. Dr. Stone is a Qualified Person, as defined by National Instrument 43-101 and has reviewed and approved the technical content.
On behalf of the Board of Directors
“Harry Barr”
Harry G. Barr
Chairman and CEO
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward Looking Statements: This release contains forward-looking statements that involve risks and uncertainties. These statements may differ materially from actual future events or results and are based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. In addition, forward-looking statements include statements in which the Company uses words such as “continue”, “efforts”, “expect”, “believe”, “anticipate”, “confident”, “intend”, “strategy”, “plan”, “will”, “estimate”, “project”, “goal”, “target”, “prospects”, “optimistic” or similar expressions. These statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others, the Company’s ability and continuation of efforts to timely and completely make available adequate current public information, additional or different regulatory and legal requirements and restrictions that may be imposed, and other factors as may be discussed in the documents filed by the Company on SEDAR (www.sedar.com), including the most recent reports that identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company does not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Investors should not place undue reliance on forward-looking statements.

VANCOUVER, BRITISH COLUMBIA–(Nov. 3, 2016) – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(FRANKFURT:M5BQ) is pleased to announce that the Company has secured new agreements with manufacturers of indoor growing equipment. These product lines will be added to Namaste’s e-commerce portals and complement the Company’s existing portfolio of vaporizers, pipes, papers and other accessories. This new product portfolio also represents a further monetization of Namaste’s customer list of approximately 250 thousand names.
US Elections
Currently, cannabis is legal for medical use in 25 states and recreational use in four states. Next week, the US will have three states voting on the legalization of medical use (Florida, Arkansas, and North Dakota) and five states voting on the legalization of recreational use of cannabis (California, Massachusetts, Arizona, Nevada, and Maine). Should all five states vote in favor of recreational marijuana, the US could have upwards of 75 million people living in states where the recreational consumption of cannabis will be legal. This represents approximately 23% of the total US population and is anticipated to advance the potential for legalization in additional states. In the US, support for the legalization of cannabis reached an all-time high of 57% in favor. Namaste’s product portfolio is ideally positioned to capitalize on these potential developments in the US.
Agreement Details
Namaste has entered into agreements with Gorilla Grow Tent Inc., SuperCloset Inc. and Kind LED Grow Lights, all leading manufacturers of the most advanced growing equipment available on the market. Namaste will initially market each of the manufacturers’ products in the US and Canada, and will receive wholesale rates on product sales. It is anticipated after the initial launch, Namaste will launch each of these brands into the twenty international markets Nasmaste currently serves.
Management Commentary
Sean Dollinger, President and CEO of Namaste, comments: “The markets for our current and new products are expanding considerably. With the acquisition of VaporSeller and URT1, we have given ourselves a substantial position in the US market which now represents 74% of our customer base. We view the upcoming election in the US as a key catalyst for our company and will continue to focus our efforts on expanding our brands in the US, which is the largest market for our products globally.”
About Gorilla Grow Tent Inc.
Gorilla Grow Tents are professionally designed grow tents that are ideal for experts and perfect for beginners and set the standard for quality and durability. Each grow tent is built with stable reinforced materials and are the strongest and safest materials available. Gorilla Grow tents have no plastic and feature a proprietary diamond reflection technology for best yield. Gorilla Grow Tents also feature a patent pending adjustable height extension kit that gives you the ability to increase your growing height from 7′ to 8′ or even 9′ tall.
About SuperCloset Inc.
Founded by Kip Anderson in 2002, SuperCloset, also known as SuperPonics, is accredited by the Better Business Bureau and maintains a perfect A+ rating, surpassing any other company in the hydroponics industry. SuperCloset is known as the leading manufacturer of Automated Superponics Systems and Grow Boxes in the world. Based in beautiful San Francisco, California, the company is in the perfect environment for combining innovative and imaginative ideologies with progressive methods of harvesting local, sustainable and organic products.
About Kind LED Grow Lights
Kind LED Grow Lights are the industry leader in indoor LED grow lights. Kind LED consulted with hundreds of professional hydroponic and soil growers to rigorously research and develop their cutting edge LED indoor grow light technology that has since revolutionized the indoor growing industry. Kind LED is widely considered the best indoor LED grow light on the market today. Kind LED Grow Lights are comprised of high powered 5 and/or 3 Watt Light Emitting Diodes featuring a proprietary intensified 12 band spectrum, including infrared and UV diodes designed for both vegetative and flowering stages of growth.
About Namaste Technologies Inc.
Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.
On behalf of the Board of Directors
Sean Dollinger, Chief Executive Officer
Further information on the Company and its products can be accessed through the links below:
FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors 5 discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.
Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
Direct: +1 (786) 389 9771
[email protected]
www.namastetechnologies.com
OTTAWA, ONTARIO–(Nov. 3, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) through its subsidiary, PhytoPain Pharma Inc. (“PPP“), is pleased to announce that it has signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations (“ACMPR“) licensed producer Aphria Inc. (“Aphria“) (TSX VENTURE:APH)(OTCQB:APHQF) for the supply of dried medical cannabis as an Active Pharmaceutical Ingredient (API) for PPP’s inhalation cannabis product PPP001. PPP001 is a medical marijuana product that the company is developing as a prescription controlled drug for inhalation using a fully assembled titanium pipe.
Aphria is a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations.Under this supply agreement with Aphria, PPP shall pursue the development of a prescription controlled inhalation drug product of medical marijuana and seek marketing approval across the world either directly or indirectly through partnerships or licensing agreements. Aphria will be the exclusive supplier of this API to PPP for the development and commercialisation of PP001.
PPP is granted an exclusive, non-transferrable, royalty free, licence to use the API in the development of PPP001. The agreement defines a purchase price during the clinical development and a volume rebate once a target volume is reached.
Both Canadian and USA prescription drug regulations impose rigorous quality systems for the manufacturing of both the API and finished drug product. These requirements include conformance to pharmaceutical Good Manufacturing Practice regulations (“GMP“) as well as demonstrating the ability of the manufacturer to ensure lot-to-lot consistency in the quality and safety of the prescription drug.
Dr. Guy Chamberland, M.Sc., Ph.D., Chief Scientific Officer and Regulatory Affairs, PhytoPain Pharma Inc., commented, “We are very pleased and excited to be working with Aphria in the development of PPP001. Developing prescription botanical based pharmaceuticals requires a high quality GMP system and well-established product specifications to ensure consistent efficacy and ultimately protect the safety of patients. Based on our assessment of Aphria, we are confident that their high quality GMP medical cannabis production facility and impressive quality assurance team will meet or exceed the expectations of both the Canadian and USA prescription drug authorities.”
“With this agreement in place, PPP is now in a solid position to submit its Clinical Trial Application (CTA) for its planned Phase I trial in healthy volunteers. The company is also on track for submitting its Pre-IND Information Package for its upcoming meeting the US FDA,” stated Dr. Chamberland.
“Aphria is excited and proud to be an integral part of advancing the scientific research being led by Dr. Chamberland and the team at Tetra Bio-Pharma. Using our proprietary and high quality medical cannabis blend supported by high calibre research is exactly what professional healthcare practitioners require to gain the confidence to prescribe medical cannabis as a pharmaceutical,” said Vic Neufeld, Chief Executive Officer, Aphria Inc.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Neither the TSX Venture Exchange (the “Exchange”) nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
André Rancourt
Chief Executive Officer
Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications
Tetra Bio-Pharma Inc.
André Audet
Executive Chairman
(613) 421-8402
Aphria Inc.
Vic Neufeld
1-844-427-4742

OTTAWA, ONTARIO–(Nov. 2, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) through its subsidiary, PhytoPain Pharma Inc. (“PPP“), is pleased to announce that it held its Scientific and Clinical Advisory Board (“CAB“) meeting on October 29th. The CAB reviewed the development program of PPP’s inhalation cannabis product PPP001. PPP001 is a medical marijuana product that the company is developing as a prescription controlled drug for inhalation using a fully assembled titanium pipe.
The Board, which is comprised of experts in clinical research, pain management as well as cancer, and neurological product drug development (ref: news release August 26, 2016), met to review and discuss the development program to date, the study design of the Phase I trial and the overall clinical development plan of PPP001. This included the exclusion and inclusion criteria of the proposed Phase I trial, the Phase 1a and 1b dosing scheme, and the pharmacokinetic and pharmacodynamic assessments. The CAB also examined the clinical rationale for the selection of the delta-9-tetrahydrocannibinol (THC) and Cannabidiol (CBD) dose levels for use in PPP001.
The CAB also reviewed the salient elements of future PPP’s Phase II and III clinical trials for the development of PPP001 in various medical conditions, including the use of medical marijuana as a second or third line therapy for cancer and HIV patients with uncontrolled pain. The CAB reports directly to the Board of Directors of the Company and will be submitting a report on the outcome of the CAB meeting in the near future.
Currently, there is only limited safety or efficacy information, if any, derived from well-controlled clinical trials available to physicians to adequately assess the benefits and risks of prescribing medical marijuana. Dr. Luc Vachon, President of the CAB commented: ²the members of the CAB are very pleased and excited to be participating in a full pharmaceutical approach on the development of medical marijuana as a prescription drug. The members expressed that the clinical development plan used by PPP – supported by a formal regulatory path – will help generate the type of clinical information required by physicians.²
“This team of scientific and clinical experts provided us with excellent guidance on the development program. We are pleased to recommend to the Board of Directors that PPP is ready to submit the Clinical Trial Application (CTA) for the conduct of its Phase I trial in healthy human volunteers,” stated Dr. Chamberland, Chief Scientific Officer and Regulatory Affairs.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
André Rancourt
Chief Executive Officer
(613) 421-8402
Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications
(613) 421-8402
Tetra Bio-Pharma Inc.
André Audet
Executive Chairman
(613) 421-8402